Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
10595954 | Bioorganic & Medicinal Chemistry Letters | 2013 | 5 Pages |
Abstract
N-(Pyridin-2-yl) arylsulfonamides 1 and 2 (PF-915275) were identified as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1. A screen for bioactivation revealed that these compounds formed glutathione conjugates. This communication presents the results of a risk benefit analysis carried out to progress 2 (PF-915275) to a clinical study and the strategies used to eliminate reactive metabolites in this series of inhibitors. Based on the proposed mechanism of bioactivation and structure-activity relationships, design efforts led to N-(pyridin-2-yl) arylsulfonamides such as 18 and 20 that maintained potent 11β-hydroxysteroid dehydrogenase type 1 activity, showed exquisite pharmacokinetic profiles, and were negative in the reactive metabolite assay.
Keywords
Related Topics
Physical Sciences and Engineering
Chemistry
Organic Chemistry
Authors
Sajiv K. Nair, Jean J. Matthews, Stephan J. Cripps, Hengmiao Cheng, Jacqui E. Hoffman, Christopher Smith, Stanley Kupchinsky, Michael Siu, Wendy D. Taylor, Yong Wang, Theodore O. Johnson, Klaus R. Dress, Martin P. Edwards, Sue Zhou, Natilie A. Hosea,